OBJECTIVES: To assess associations between cerebrospinal fluid (CSF) biomarker levels and MRI-based whole-brain atrophy rate in mild cognitive impairment (MCI) and Alzheimer's disease (AD). METHODS: We included 99 patients (47 AD, 29 MCI, 23 controls) who underwent lumbar puncture at baseline and repeat MRI. A subgroup of 48 patients underwent a second lumbar puncture. CSF levels of beta-amyloid(1-42) (A beta(1-42)), tau and tau phosphorylated at threonine-181 (P-tau(181)), and whole-brain atrophy rate were measured. RESULTS: Across groups, baseline A beta(1-42) and tau were modestly associated with whole-brain atrophy rate. Adjusted for age, sex and diagnosis, we found no association between A beta(1-42) or tau, and whole-brain atrophy rate. By contrast, high CSF levels of P-tau(181) showed a mild association with a lower whole-brain atrophy rate in AD but not in controls or MCI patients. Finally, whole-brain atrophy rate was associated with change in MMSE, but change in CSF biomarker levels was not. CONCLUSIONS: Whole-brain atrophy rate and CSF levels of A beta(1-42,) tau or P-tau(181) provide complementary information in patients with MCI and AD. (c) 2008 Elsevier Inc. All rights reserved.
OBJECTIVES: To assess associations between cerebrospinal fluid (CSF) biomarker levels and MRI-based whole-brain atrophy rate in mild cognitive impairment (MCI) and Alzheimer's disease (AD). METHODS: We included 99 patients (47 AD, 29 MCI, 23 controls) who underwent lumbar puncture at baseline and repeat MRI. A subgroup of 48 patients underwent a second lumbar puncture. CSF levels of beta-amyloid(1-42) (A beta(1-42)), tau and tau phosphorylated at threonine-181 (P-tau(181)), and whole-brain atrophy rate were measured. RESULTS: Across groups, baseline A beta(1-42) and tau were modestly associated with whole-brain atrophy rate. Adjusted for age, sex and diagnosis, we found no association between A beta(1-42) or tau, and whole-brain atrophy rate. By contrast, high CSF levels of P-tau(181) showed a mild association with a lower whole-brain atrophy rate in AD but not in controls or MCI patients. Finally, whole-brain atrophy rate was associated with change in MMSE, but change in CSF biomarker levels was not. CONCLUSIONS: Whole-brain atrophy rate and CSF levels of A beta(1-42,) tau or P-tau(181) provide complementary information in patients with MCI and AD. (c) 2008 Elsevier Inc. All rights reserved.
Authors: Barbara J Snider; Anne M Fagan; Catherine Roe; Aarti R Shah; Elizabeth A Grant; Chengjie Xiong; John C Morris; David M Holtzman Journal: Arch Neurol Date: 2009-05
Authors: P Vemuri; H J Wiste; S D Weigand; L M Shaw; J Q Trojanowski; M W Weiner; D S Knopman; R C Petersen; C R Jack Journal: Neurology Date: 2009-07-28 Impact factor: 9.910
Authors: Raymond Y Lo; Alan E Hubbard; Leslie M Shaw; John Q Trojanowski; Ronald C Petersen; Paul S Aisen; Michael W Weiner; William J Jagust Journal: Arch Neurol Date: 2011-06-13
Authors: W J P Henneman; H Vrenken; J Barnes; I C Sluimer; N A Verwey; M A Blankenstein; M Klein; N C Fox; P Scheltens; F Barkhof; W M van der Flier Journal: Neurology Date: 2009-09-22 Impact factor: 9.910
Authors: Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski Journal: Lancet Neurol Date: 2010-01 Impact factor: 44.182
Authors: Anders M Fjell; Kristine B Walhovd; Christine Fennema-Notestine; Linda K McEvoy; Donald J Hagler; Dominic Holland; Kaj Blennow; James B Brewer; Anders M Dale Journal: Cereb Cortex Date: 2010-01-04 Impact factor: 5.357